Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer

Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, director of the breast cancer and gynecologic cancer research program at the Sarah Cannon Research Institute, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer.

OP-1250 is a novel therapy that is different to other agents, says Hamilton. It is a complete estrogen receptor (ER) antagonist with unique properties that shows promise for this particular patient population. OP-1250 has also demonstrated activity preclinically in both wild-type and ESR1 models, and it turns off both the AF1 and AF2 domain, says Hamilton.